Affimed - AFMD Stock Forecast, Price & News

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Affimed in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AFMD shares.
View AFMD analyst ratings or view top-rated stocks.

6 equities research analysts have issued 12-month price objectives for Affimed's shares. Their AFMD share price forecasts range from $2.00 to $8.00. On average, they predict the company's share price to reach $5.83 in the next year. This suggests a possible upside of 667.5% from the stock's current price.
View analysts price targets for AFMD or view top-rated stocks among Wall Street analysts.

Affimed's stock was trading at $1.24 at the beginning of 2023. Since then, AFMD stock has decreased by 38.7% and is now trading at $0.76.
View the best growth stocks for 2023 here.

Affimed saw a increase in short interest in February. As of February 28th, there was short interest totaling 3,780,000 shares, an increase of 21.5% from the February 13th total of 3,110,000 shares. Based on an average daily trading volume, of 1,700,000 shares, the days-to-cover ratio is currently 2.2 days.
View Affimed's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 23rd 2023.
View our AFMD earnings forecast.

Affimed will be holding an earnings conference call on Thursday, March 23rd at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

Affimed (NASDAQ:AFMD) announced its earnings results on Wednesday, November, 10th. The biopharmaceutical company reported ($0.14) EPS for the quarter, missing analysts' consensus estimates of ($0.13) by $0.01. The biopharmaceutical company earned $10.21 million during the quarter, compared to analyst estimates of $11.79 million. Affimed had a negative net margin of 189.04% and a negative trailing twelve-month return on equity of 48.46%. During the same quarter in the prior year, the business posted ($0.08) EPS.

ETFs with the largest weight of Affimed (NASDAQ:AFMD) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC) and Invesco Nasdaq Future Gen 200 ETF (QQQS).ALPS Medical Breakthroughs ETF (SBIO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Affimed investors own include Novavax (NVAX), JetBlue Airways (JBLU), SentinelOne (S), American International Group (AIG), Sorrento Therapeutics (SRNE), Catalyst Pharmaceuticals (CPRX), Amarin (AMRN), Rigel Pharmaceuticals (RIGL), Viking Therapeutics (VKTX) and Lipocine (LPCN).

Affimed trades on the NASDAQ under the ticker symbol "AFMD."

Affimed's stock is owned by a variety of institutional and retail investors. Top institutional investors include 683 Capital Management LLC (7.29%), Point72 Asset Management L.P. (3.41%), Boone Capital Management LLC (2.33%), Morgan Stanley (1.71%), Millennium Management LLC (1.67%) and Geode Capital Management LLC (1.11%).

Shares of AFMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AFMD stock can currently be purchased for approximately $0.76.

Affimed (NASDAQ:AFMD) has a market capitalization of $93.80 million and generates $47.76 million in revenue each year. The biopharmaceutical company earns $-68,060,000.00 in net income (profit) each year or ($0.63) on an earnings per share basis.

The company employs 197 workers across the globe.

Affimed's mailing address is TECHNOLOGIEPARK IM NEUENHEIMER FELD 582, HEIDELBERG 2M, 69120. The official website for the company is www.affimed.com. The biopharmaceutical company can be reached via phone at 496221674360, via email at ir@affimed.com, or via fax at 49-6221-653-0777.